Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Gross margin

Gross margin at other companies

AbbVie logo
AbbVieABBV
71.5%+0.5pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
87.2%-3.4pp
HRO
HarrowHROW
74.1%-0.4pp
Warby Parker logo
Warby ParkerWRBY
54.7%+0.2pp
Journey Medical Corporation logo
Journey Medical CorporationDERM
65.4%-1.0pp
PTH
Pelthos TherapeuticsPTHS
79.6%—

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×